FBI opens probe into death of Colts owner Jim Irsay as team operations continue under family leadership

Federal authorities have launched an investigation into the May 2025 death of longtime Indianapolis Colts owner Jim Irsay, with the scope of the inquiry focused on his use of prescription medications and his treatment by a California-based recovery physician in the months before he died. People familiar with the matter say the inquiry is being handled through a federal grand jury process, a step that allows prosecutors to compel documents and testimony. The Colts have acknowledged the federal interest and said neither the club nor current employees have been subpoenaed.

Focus of the investigation

Documents issued through a federal grand jury seek records related to Irsay’s substance use, his medical care, and his relationship with a physician who treated him during his final year. Investigators have examined prescriptions – including opioids and ketamine – allegedly provided in that period, and have conducted interviews in Indianapolis as part of the case. The inquiry is expected to test whether prescribing and treatment decisions complied with federal controlled-substance standards enforced by the Controlled Substances Act, which governs how powerful medications can be dispensed, monitored and recorded in the United States.

What is known about Irsay’s death

• Irsay died in May 2025 at age 65 in Beverly Hills, California, where he had been receiving medical care.
• His death certificate cited cardiac arrest associated with pneumonia and underlying heart issues.
• No autopsy was performed, and local authorities closed their initial inquiry, finding no immediate basis for criminal charges.

The absence of an autopsy and the decision to close the original case have placed additional attention on how his medical care was structured in the months leading up to his death and on whether key clinical decisions were appropriately documented.

Implications for the franchise

Day-to-day football and business operations have remained with Irsay’s daughters – Carlie Irsay‑Gordon, Casey Foyt and Kalen Jackson – who held senior roles prior to his passing and have since assumed leadership of the team. The sisters had already been visible stewards of the franchise, participating in ownership meetings and major organizational decisions in recent years.

On-field planning and front-office work have continued within established structures, offering continuity during the postseason calendar and into the pre-draft period. General manager and coaching staff responsibilities remain unchanged, and the club’s football operations are described internally as “business as usual” while the federal process plays out.

Any formal changes to club ownership are subject to approval under National Football League governance rules, which require that controlling owners be vetted and approved by a supermajority of fellow clubs. For now, the current arrangement preserves decision-making stability around roster building, coaching support and longer-term stadium and commercial commitments, even as the Irsay family manages legal and reputational risk associated with the inquiry.

Broader context around player welfare and governance

Irsay had spoken publicly for years about his battles with addiction and funded mental health initiatives, positioning himself as a prominent NFL owner willing to discuss substance use and recovery in personal terms. The federal investigation centers on medical decision-making and prescription oversight rather than competitive matters, but it inevitably intersects with the sport’s broader emphasis on health, safety and duty of care for players, staff and executives.

For teams, this case underscores how off‑field medical relationships – especially involving controlled substances or experimental therapies – can invite scrutiny that extends beyond club walls. It also highlights the layered oversight environment in which professional sports now operate: club medical staffs answer to league policies, while independent outside providers remain accountable to state medical boards and federal regulators. Any findings about lapses in prescribing or monitoring practices could inform how franchises structure future relationships with external recovery specialists, pain-management clinics and concierge physicians.

What the league and club are navigating now

• Law enforcement’s work is ongoing; no charges have been announced, and federal officials have not publicly commented on potential targets of the investigation.
• The Colts say they have not been contacted directly with subpoenas and that no current employees have received them, but the organization is monitoring developments through counsel.
• Leadership continuity under Irsay’s daughters positions the franchise to maintain routine football operations while preparing for possible legal, insurance and governance questions that could arise from the probe.

As the investigation proceeds, the central questions are expected to remain on medical oversight, prescribing practices, and the professional responsibilities attached to high‑profile patients. For an NFL organization with significant community and commercial reach, the outcome matters not only for the Irsay family but for the evolving standards by which elite sports manage health, recovery and accountability off the field. Any eventual conclusions – whether they result in criminal charges, regulatory findings, or no action at all – are likely to feed into ongoing debates over how much transparency and independent review should surround medical care for some of the most prominent figures in American sports.